Syn2bio Spolka Akcyjna (S2B)

Overview

Syn2bio S.A. is a biotechnology enterprise engaged in pioneering research and the commercialization of innovative solutions for cardiac care. Located in Warsaw, Poland, and incorporated in 2025, the company specializes in developing advanced diagnostic tools for heart disease, particularly through its flagship project, the cardiotracer project. This initiative focuses on a novel radiopharmaceutical known as Cardiac Marker, which enhances diagnostic testing for myocardial perfusion and aids in identifying coronary artery disease. In addition to its primary focus on cardiovascular diagnostics, Syn2bio S.A. operates The Centre for Research on New Compounds, dedicated to the discovery, analysis, registration, and launch of new pharmaceutical compounds as medicinal products, thereby broadening its impact on the healthcare sector.

Products and Services

• Cardiac Marker:

  This radiopharmaceutical is specifically designed for diagnostic applications related to heart disease. It plays a crucial role in myocardial perfusion tests, helping healthcare providers accurately assess blood flow to the heart muscle, which is vital for diagnosing conditions like coronary artery disease.

• Cardiotracer Project:

  A significant endeavor under the banner of Syn2bio S.A., this project is aimed at developing a state-of-the-art radiopharmaceutical. The cardiotracer enhances diagnostic capabilities for detecting and evaluating myocardial perfusion, ultimately facilitating better patient care and outcomes in cardiovascular health.

• Research and Development Services:

  Through The Centre for Research on New Compounds, Syn2bio S.A. undertakes extensive research to identify and develop new pharmaceutical compounds. This includes ongoing studies to assess their efficacy and safety, followed by regulatory procedures that ensure their readiness for market introduction as effective medicinal products.

• Market Launch Support:

  The company provides comprehensive support for the market launch of new pharmaceuticals developed within its research facilities. This involves strategic planning and execution that align with regulatory guidelines to ensure successful entry into the healthcare market.